There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH) and Aptose Biosciences (APTO) with bullish sentiments.
UnitedHealth (UNH)
In a report issued on June 10, Frank Morgan from RBC Capital maintained a Buy rating on UnitedHealth, with a price target of $473.00. The company’s shares closed last Friday at $397.89.
According to TipRanks.com, Morgan is a 5-star analyst with an average return of 23.5% and a 68.3% success rate. Morgan covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Fresenius Medical Care, and Acadia Healthcare.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for UnitedHealth with a $444.79 average price target, representing a 10.3% upside. In a report issued on June 1, Merrill Lynch also reiterated a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Aptose Biosciences (APTO)
RBC Capital analyst Gregory Renza maintained a Buy rating on Aptose Biosciences on June 11 and set a price target of $9.00. The company’s shares closed last Friday at $3.76, close to its 52-week low of $3.39.
According to TipRanks.com, Renza is a 3-star analyst with an average return of 5.0% and a 34.1% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Inovio Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a $11.14 average price target, a 164.0% upside from current levels. In a report issued on June 11, JonesTrading also reiterated a Buy rating on the stock with a $14.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
